This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (37)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Dermatologic Disorders  • Dermatologic Disorders, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Arch Dermatol. 2003;139:928-930.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

MOST "NEW" diseases are the product of humans intervention. New drug reactions, diseases in transplant recipients, and even new epidemics (eg, human immunodeficiency virus disease) have been brought about or facilitated by changes in human behavior. The condition currently called nephrogenic fibrosing dermopathy (NFD) will likely be an example of such a condition, but the proof is not in yet.

In 1997, nephrologists at a medical center in southern California began seeing patients who had extensive cutaneous induration. Most of these patients were recipients of renal transplants, and in many cases the transplants had been rejected. Biopsy results of several of these patients led to the conclusion that they all had the same condition, one that resembled or perhaps was scleromyxedema. From the outset, it was clear that the condition was distinct from morphea or scleroderma.

Shortly thereafter, the pathologists who saw these cases sent me sections of the biopsy . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Nephrogenic Fibrosing Dermopathy With Systemic Involvement
William W. Ting, Mary Seabury Stone, Kathi C. Madison, and Kevin Kurtz
Arch Dermatol. 2003;139(7):903-906.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Systemic Sclerosis: Environmental Factors
MORA
The Journal of Rheumatology 2009;36:2383-2396.
ABSTRACT | FULL TEXT  

Estimates of Risk, Empirical Treatment Observations, and Unexpected Laboratory Findings Reveal the Complexity of Nephrogenic Systemic Fibrosis
High
Arch Dermatol 2009;145:1178-1182.
FULL TEXT  

Nephrogenic Systemic Fibrosis after Gadopentetate Dimeglumine Exposure: Case Series of 36 Patients
Abujudeh et al.
Radiology 2009;253:81-89.
ABSTRACT | FULL TEXT  

Acute phase reaction to gadolinium-DTPA in dialysis patients
Steen et al.
Nephrol Dial Transplant 2009;24:1274-1277.
ABSTRACT | FULL TEXT  

Nephrogenic Systemic Fibrosis: A Report of 29 Cases
Shabana et al.
Am. J. Roentgenol. 2008;190:736-741.
ABSTRACT | FULL TEXT  

Nephrogenic Systemic Fibrosis: A Population Study Examining the Relationship of Disease Development to Gadolinium Exposure
Deo et al.
CJASN 2007;2:264-267.
ABSTRACT | FULL TEXT  

Gadodiamide-Associated Nephrogenic Systemic Fibrosis: Why Radiologists Should Be Concerned
Broome et al.
Am. J. Roentgenol. 2007;188:586-592.
ABSTRACT | FULL TEXT  

Nephrogenic fibrosing dermopathy and high-dose erythropoietin therapy.
Swaminathan et al.
ANN INTERN MED 2006;145:234-235.
FULL TEXT  

Gadolinium - a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?
Grobner
Nephrol Dial Transplant 2006;21:1104-1108.
FULL TEXT  

Case 35-2004 - A 68-Year-Old Man with End-Stage Renal Disease and Thickening of the Skin
Moschella et al.
NEJM 2004;351:2219-2227.
FULL TEXT